March 26, 2018 07:28 AM EDTUpdated 09:12 AM
R&D

Pro­tag­o­nist aborts lead ul­cer­a­tive col­i­tis pro­gram af­ter drug fiz­zles in PhI­Ib, stock craters

Brittany Meiling

The lead ther­a­py at Pro­tag­o­nist has flunked a mid-stage tri­al, push­ing the Newark-based com­pa­ny to pull the plug on its ul­cer­a­tive col­i­tis drug PTG-100. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times